Convenient access both to highly antimalaria-active 10- arylaminoartemisinins, and to 10-alkyl ethers including artemether, arteether, and artelinate

ChemBioChem

Volumn 6, Issue 4, 2005, Pages 659-667

  Haynes, Richard K ^a   Chan, Ho Wai ^a   Ho, Wing Yan ^a   Ko, Cliff Ki Fung ^a   Gerena, Lucia ^b   Kyle, Dennis E ^b   Peters, Wallace ^c   Robinson, Brian L ^c  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c NORTHWICK PARK INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Antimalarial; Artemisinin; Glycosylamine; Phase transfer catalysis; Synthesis

Indexed keywords

10ALPHA (4' FLUOROPHENYL)AMINO 10 DEOXO 10 DIHYDROARTEMISININ; ANTIMALARIAL AGENT; ARTEETHER; ARTELINATE; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG STRUCTURE; MALARIA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTIMALARIALS; ARTEMISININS; MALARIA; MICE; MOLECULAR STRUCTURE; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; SESQUITERPENES;

ARTESUNATE; PLASMODIUM BERGHEI;

EID: 21044434332     PISSN: 14394227     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbic.200400366     Document Type: Article

References (104)

1. For reviews, see inter alia: D. L. Klayman, Science 1985, 225, 1049-1055;
2. X.-D. Luo, C.-C. Shen, Med. Res. Rev. 1987, 7, 29-52;
3. P. I. Trigg, Econ. Med. Plant Res. 1989, 3, 20-55;
4. S. S. Zaman, R. P. Sharma, Heterocycles 1991, 32, 1593-1638;
5. A. R. Butler, Y.-L. Wu, Chem. Soc. Rev. 1992, 21, 85-90;
6. Y.-L. Wu, Y. Li, Med. Chem. Res. 1995, 5, 569-586;
7. S. R. Meshnick, T. E. Taylor, S. Kamchonwongpaisan, Microbiol. Rev. 1996, 60, 301-315;
8. H. Ziffer, R. J. Highet, D. L. Klayman, Prog. Chem. Org. Nat. Prod. 1997, 72, 121-214;
9. Y. Li, Y.-L. Wu, Méd. Trop. (Marseille) 1998, 55, Supplement 3, 9-12;
10. G. H. Posner, Expert Opin. Ther. Pat. 1998, 8, 1487-1493;
11. M. A. van Agtmael, T. A. Eggelte, C. J. van Boxtel, Trends Pharmacol. Sci. 1999, 20, 199-205;
12. A. K. Bhattacharya, R. P. Sharma, Hererocycles 1999, 51, 1681-1745;
13. Y. Li, Y.-L. Wu, Curr. Med. Chem. 2003, 10, 2197-2231;
14. P. M. O'Neill, G. H. Posner, J. Med. Chem. 2004, 47, 2945-2964.
15. J. A. Vroman, M. Alvim-Gaston, M. A. Avery, Curr. Pharm. Des. 1999, 5, 101-138;
16. M. A. Avery, M. Alvim-Gaston, J. R. Woolfrey, Adv. Med. Chem. 1999, 4, 125-217.
17. A. J. Lin, D. L. Klayman, W. K. Milhous, J. Med. Chem. 1987, 30, 2147-2150.
18. R. K. Haynes, Curr. Opin. Infect. Dis. 2001, 14, 719-726.
19. See, for example, the numerous excellent examples of chemically robust artemisinin derivatives prepared by Bégué, Bonnet-Delpon, and co-workers: G. Magueur, B. Crousse, S. Charneau, P. Grellier, J.-P. Bégué, D. Bonnet-Delpon, J. Med. Chem. 2004, 47, 2694-2699;
20. G. Magueur, B. Crousse, S. Charneau, P. Grellier, J.-P. Bégué, D. Bonnet-Delpon, Exp. Opin. Ther. Pat. 2003, 13, 1763-1769, and references therein.
21. Malaria Unit, Division of Control of Tropical Disease, World Health Organization, The Use of Artemisinin and Its Derivatives as Anti-Malarial Drugs, Report of a Joint CTD/DMP/TDR Informal Consultation, Geneva, 1998.
22. J. A. Vroman, I. A. Khan, M. A. Avery, Tetrahedron Lett. 1997, 38, 6173-6176;
23. J. A. Vroman, I. Khan, M. A. Avery, Synlett 1997, 1438-1440;
24. J. A. Vroman, H. N. El Sohly, M. A. Avery, Synth. Commun. 1998, 28, 1555-1562.
25. M. A. Avery, W. K. M. Chong, J. E. Bupp, J. Chem. Soc. Chem. Commun. 1990, 1487-1489;
26. M. A. Avery, W. K. M. Chong, G. Detre, Tetrahedron Lett. 1990, 31, 1799-1802;
27. M. A. Avery, F. Gao, W. K. M. Chong, T. F. Hendrickson, W. D. Inman, P. Crews, Tetrahedron 1994, 50, 957-972;
28. M. A. Avery, S. Mehrotra, T. L. Johnson, J. D. Bonk, J. A. Vroman, R. Miller, J. Med. Chem. 1996, 39, 4149-4155;
29. M. A. Avery, M. Alvim-Gaston, C. R. Rodrigues, E. J. Barreiro, F. E. Cohen, Y. A. Sabnis, J. R. Woolfrey, J. Med. Chem. 2002, 45, 292-303.
30. P. Olliaro, R. K. Haynes, B. Meunier, Y. Yuthavong, Trends Parasitol. 2001, 17, 121-126;
31. P. Olliaro, R. K. Haynes, B. Meunier, Y. Yuthavong, Trends Parasitol. 2001, 17, 267-268.
32. R. K. Haynes, D. Monti, D. Taramelli, N. Basilico, S. Parapini, P. Olliaro, Antimicrob. Agents Chemother. 2003, 47, 1175;
33. R. K. Haynes, D. Monti, D. Taramelli, N. Basilico, S. Parapini, P. Olliaro, Antimicrob. Agents Chemother. 2003, 47, 2712-2713.
34. R. J. Roth, N. Acton, J. Nat. Prod. 1989, 52, 1183-1185;
35. R. J. Roth, N. Acton, J. Chem. Educ. 1991, 68, 612.
36. R. K. Haynes, S. C. Vonwiller, Cyclic Peroxy Acetal Lactone and Ether Compounds, WO 91/04970 18 April, 1991 [Priority date 27 September 1989, AU P J6595);
37. R. K. Haynes, S. C. Vonwiller, J. Chem. Soc. Chem. Commun. 1990, 451-453;
38. R. K. Haynes, S. C. Vonwiller, Synlett, 1992, 481-483;
39. R. K. Haynes, S. C. Vonwiller, Irans. R. Soc. Trop. Med. Hyg. 1995, 88, S23-S26;
40. R. K. Haynes, G. R. King, S. C. Vonwiller, J. Org. Chem. 1994, 59, 4743-4748;
41. R. K. Haynes, S. C. Vonwiller, H.-J. Wang, Tetrahedron Lett. 1995, 36, 4641-4642;
42. S. C. Vonwiller, J. A. Warner, S. T. Mann, R. K. Haynes, J. Am. Chem. Soc. 1995, 117, 11098-11105;
43. R. K. Haynes, K.-P. Lam, K.-Y. Wu, L. L. Yeung, Tetrahedron 1999, 55, 10087-10100.
44. R. K. Haynes, S. C. Vonwiller, Acc. Chem. Res. 1997, 30, 73-79.
45. M. Jung, D. A. Bustos, H. N. El Sohly, J. D. McChesney, Synlett 1990, 743-744;
46. M. Jung, D. Yu, D. A. Bustos, H. N. El Sohly, J. D. McChesney, Bioorg. Med. Chem. Lett. 1991, 1, 741-744;
47. M. Jung, A. C. Freitas, J. D. McChesney, H. N. El Sohly, Heterocycles 1995, 39, 23-29;
48. M. Jung, R. F. Schinazi, Bioorg. Med. Chem. Lett. 1994, 4, 931-934.
49. M. Jung, Biorg. Med. Chem. Lett. 1997, 7, 1091-1094.
50. M. Jung, S. Lee, J. Ham, K. Lee, H. Kim, S. K. Kim, J. Med. Chem. 2003, 46, 987-994.
51. R. J. Roth, N. Acton, Planta Med. 1987, 53, 501;
52. R. J. Roth, N. Acton, J. Chem. Educ. 1989, 66, 349;
53. R. K. Haynes, S. C. Vonwiller, G. R. King, H.-J. Wang, Planta Med. 1993, 59, 562-563.
54. M. Jung, K. Lee, H. Kendrick, B. L. Robinson, S. L. Croft, J. Med. Chem. 2002, 45, 4940-4944.
55. R. K. Haynes, R. Carter, Audit of Artemisinin Producers in the People's Republic of Vietnam, June 7-June 11, 1999, Knoll Liestal, Chemotherapy of Malaria/Tropical Diseases Research, WHO Geneva, 1999.
56. DHA is available in kilogram lots from the Kunming Pharmaceutical Corporation, Kunming, P.R. China.
57. K. T. Batty, K. F. Ilett, T. M. E. Davis, J. Pharm. Pharmacol. 1996, 48, 22-26.
58. V. Leskovac, A. D. Theoharides, Comp. Biochem, Physiol. Part C Pharmacol. Toxicol. Endocrinol. 1991, 99, 383-390;
59. V. Leskovac, A. D. Theoharides, Comp. Biochem. Physiol. Part C Pharmacol. Toxicol. Endocrinol. 1991, 99, 391-396;
60. J. K. Baker, J. D. McChesney, H.-T. Chi, Pharm. Res. 1993, 10, 662-666;
61. V. Navaratnam, S. M. Mansor, N. W. Sit, J. Grace, G.-Q. Li, P. Olliaro, Clin. Pharmacokinet. 2000, 39, 255-270;
62. G. Lefevre, P. Carpenter, C. Souppart, H. Schmidli, M. McClean, D. Stypinski, Br. J. Clin. Pharmacol. 2002, 54, 485-492;
63. T. M. E. Davis, T. Q. Binh, K. F. Ilett, K. T. Batty, H. L. Phuöng, G. M. Chiswell, V. D. B. Phuong, C. Agus, Antimicrob. Agents Chemother. 2003, 47, 368-370.
64. T. G. Brewer, J. O. Peggins, S. J. Grate, J. M. Petras, B. S. Levine, P. J. Weina, J. Swearengen, M. H. Heiffer, B. O. Schuster, Trans. R. Soc. Trop. Med. Hyg. 1995, 88, 33-36;
65. T. G. Brewer, S. J. Grate, J. O. Peggins, P. J. Weina, J. M. Petras, B. S. Levine, M. H. Heiffer, B. G. Schuster, Am. J. Trop. Med. Hyg. 1995, 51, 251-259;
66. R. F. Genovese, D. B. Newman, T. G. Brewer, Pharmacol. Biochem. Behav. 2000, 67, 37-44;
67. A. Nontprasert, A. Pukrittayakamee, M. Nosten-Bertrand, S. Vanijanonta, N. J. White, Am. J. Trop. Med. Hyg. 2000, 62, 409-412.
68. G. Schmuck, R. K. Haynes, Neurotoxic. Res. 2000, 2, 37-49;
69. G. Schmuck, E. Roehrdanz, R. K. Haynes, R. Kahl, Antimicrob. Agents Chemother. 2002, 46, 821-827.
70. K. Ramu, J. K. Baker, J. Med. Chem. 1995, 38, 1911-1921.
71. Lipophilicity is important in modulation of neurotoxicity (ref. [4]), although the presence or absence of an oxygen atom at C-10 is irrelevant (cf. refs. [16] and [18]). Theoretical calculations underpin this precept, see A. K. Bhattacharjee, J. M. Karle, Chem. Res. Toxicol. 1999, 12, 422-428.
72. Y.-H. Yang, Y. Li, Y.-S. Shi, J.-D Yang, B.-A. Wu, Bioorg. Med. Chem. Lett. 1995, 5, 1791-1794.
73. For the preparation of C-10 arylamino derivatives bearing bromine at C-9, see A. J. Lin, L.-Q. Li, D. L. Klayman, C. F. George, J. L. Flippen-Anderson, J. Med. Chem. 1990, 33, 2610-2614. Whilst these compounds display good efficacy in vitro, they have no significant activity in vivo.
74. R. K. Haynes, W. L. Lam, C-10 Halogen, Amino and Carbon Substituted Derivatives of Artemisinin for Treatment of Malaria, Coccidiosis, and Neosporosis European Patent appl., 98305596.3 July 14, 1998;
75. R. K. Haynes, W. L. Lam, W. W. L. Hsiao, Artemisinin Derivatives Bearing DNA Intercalating and Binding Groups Displaying Anticancer Activity European Patent appl. 98305593.0 July 14, 1998;
76. R. K. Haynes, H. W. Chan, W. L. Lam, H. W. Tsang, M. K. Cheung, Synthesis and Antiparasitic Activity of Artemisinin Derivatives, PCT Int. Appl., WO 2000004 January 24, 2000.
77. R. K. Haynes, W.-Y. Ho, H.-W. Chan, B. Fugmann, J. Stetter, S. L. Croft, L. Vivas, W. Peters, B. L. Robinson, Angew. Chem. 2004, 116, 1405-1409;
78. Angew. Chem. Int. Ed. 2004, 43, 1381-1385.
79. Y. Li, Y.-M. Zhu, H.-J. Jiang, J.-P. Pan, G.-S. Wu, J.-M. Wu, Y.-L. Shi, J.-D. Yang, B.-A. Wu, J. Med. Chem. 2000, 43, 1635-1640.
80. R. K. Haynes, H. W. Chan, K. Cheung, W. L. Lam, K. Soo, H. W. Tsang, A. Voerste, I. D. Williams, Eur. J. Org. Chem. 2002, 113-132.
81. S. Hindley, S. A. Ward, R. C. Storr, N. L. Searle, P. G. Bray, B. K. Park, J. Davies, P. M. O'Neill, J. Med. Chem. 2002, 45, 1052-1063.
82. P. Collins, R. Ferrier, Monosaccharides: Their Chemistry and Their Roles in Natural Products, Wiley, Chichester, 1995, p. 108, and references therein.
83. C. F. Baes, R. E. Mesmer, The Hydrolysis of Cations, Wiley, New York, 1976, p. 129.
84. Y.-P. Hong, S. Collins, Lanthanum(III) Triflate in Encyclopedia of Reagents for Organic Synthesis, Wiley Interscience, http://www.mrw.interscience. wiley.com/eros/main.htm
85. J. Hirsch, E. Petrakova, M. S. Feather, C. L. Barns, Carbohydr. Res. 1995, 267, 17-25;
86. J. A. Serrano, M. Jimenez, E. Roman, J. Carbohydr. Chem. 1997, 16, 1051-1059;
87. M. E. Jung, E. Yang, B. T. Vu, M. Kiankarimi, E. Spyrou, J. Kaunitz, J. Med. Chem. 1999, 42, 3899-3909;
88. A. K. Sah, C.P. Rao, P. K. Saarenketo, E. K. Wegelius, K. Rissanen, E. Kolehmainen, J. Chem. Soc. Dalton Trans. 2000, 3681-3687.
89. A. Lubineau, J. Augé, B. Drouillat, Carbohydr. Res. 1995, 266, 211-219.
90. C. M. Starks, C. L. Liotta, M. Halpern, Phase Transfer Catalysis: Fundamentals, Applications and Industrial Perspectives, Chapman & Hall, New York, 1994;
91. Y. Sasson, R. Neumann, Handbook of Phase Transfer Catalysis, Blackie, London, 1997.
92. R. K. Haynes, H.-W. Chan, M.-K. Cheung, S.-K. Chung, W.-L. Lam, H.-W. Tsang, A. Voerste, I. D. Williams, Eur. J. Org. Chem. 2003, 2098-2114.
93. Y. Li, P.-L. Yu, Y.-X. Chen, L.-Q. Li, Y.-Z. Gai, D. S. Wang, Y.-P. Zheng, Yaoxue Xuebao 1981, 16, 429-439;
94. China Co-operative Research Group on Qinghaosu and its Derivatives as Antimalarials, J. Tradit. Chin. Med. 1982, 2, 9-16.
95. A. Brossi, B. Venugopalan, L. Dominguez Gerpe, H. J. C. Yeh, J. L. Flippen-Anderson, P. Buchs, X. D. Luo, W. Milhous, W. Peters, J. Med. Chem. 1988 31, 645-650.
96. P. G. Kremsner, S. Krishna, Lancet 2004, 364, 285-294.
97. Q.-G. Li, J. O. Peggins, L. L. Fleckenstein, K. J. Masonic, M. H. Heiffer, T. G. Brewer, J. Pharm. Pharmacol. 1998, 50, 173-182;
98. Q.-G. Li, J. O. Peggins, A. J. Lin, K. J. Masonic, K. M. Trotman, T. G. Brewer, Trans. R. Soc. Trop. Med. Hyg. 1998, 92, 332-340.
99. 10) are determined with a nonlinear logistic dose-response-analysis program.
100. -1 sc and po is used, which provides a preliminary evaluation of relative activity of compounds administered by each route, relative activities between compounds, and activities relative to the artesunate standard. The Peters four-day test for blood schizontocidal activity is then conducted in which mice are treated daily subcutaneously or orally from the day of infection (D0) through D+3. Results are evaluated on the basis of parasite counts in peripheral blood on D+4. For both screening and the four-day test, screens are also carried out with mice infected with the chloroquine-resistant NS species of P.yoelii: W. Peters, B. L. Robinson in Handbook of Animal Models of Infection Section VI: Parasitic Infection Models (Eds.: O. Zak, M. Sande), Academic Press, London, 1999, pp. 756-771.
101. S. Krishna, A.-C. Uhlemann, R. K. Haynes, Drug Resist. Updates 2004, 7, 233-244.
102. U. Eckstein-Ludwig, R. J. Webb, I. D. A. van Goethem, J. M. East, A. G. Lee, M. Kimura, P. M. O'Neill, P. G. Bray, S. A. Ward, S. Krishna, Nature 2003, 424, 957-961.
103. The United States Pharmacopeia XXII, Mack Printing, Rockville, MD, 1990, pp. 1784-1785.
104. Work carried out by Wing-Yan Ho.